FDA orders new warnings on four drugs tied to fungal infection

09/4/2008 | Wall Street Journal (free content), The · NYTimes.com

The FDA called for stronger warnings on the labels of Johnson & Johnson's Remicade, Abbott Laboratories' Humira, Amgen and Wyeth's Enbrel and UCB's Cimzia to inform patients about the risk of developing histoplasmosis, a harmful fungal infection. The drugs, also known as tumor necrosis factor blockers, are approved in the U.S. for treating rheumatoid arthritis and Crohn's disease. The drugmakers are cooperating with the FDA for compliance, an agency official said.

View Full Article in:

Wall Street Journal (free content), The · NYTimes.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
In house Compliance Officer
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC